Next generation Sepsis pathogen diagnostics Revolutionary device for rapid dete...
Next generation Sepsis pathogen diagnostics Revolutionary device for rapid detection of Sepsis
49M patients are diagnosed with Sepsis and 11M die annually worldwide and costs over €30 billion to treat. This is a senseless tragedy as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.
SepTec is the gr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto SepTec
Duración del proyecto: 33 meses
Fecha Inicio: 2021-03-17
Fecha Fin: 2023-12-31
Líder del proyecto
FISC-Ireland Limited
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
49M patients are diagnosed with Sepsis and 11M die annually worldwide and costs over €30 billion to treat. This is a senseless tragedy as 80% of sepsis deaths could be prevented with rapid diagnosis and treatment.
SepTec is the groundbreaking, cost-effective technology required to provide the solution.
SepTec is a patent-pending in-vitro diagnostic device that screens blood for the diagnosis of sepsis infection, detecting and identifying pathogens within 15 minutes at very low concentrations (<10 CFU/ml) without the need complicated lab tests. Preliminary health economics research shows that our rapid Sepsis infection diagnosis will result in patients receiving the correct treatment between 2 and 4.5 days earlier than in current protocols (resulting in a consequent 50% reduction in mortality rate), 25 times fewer patients receiving unnecessary antibiotics and a healthcare saving between €17-40m per 5m population.
The global point of care market is expected to be valued €50.51bn by year 2026, (CAGR of 9.6%). Within this market, the market for point-of-care tests (POCT) for infectious diseases (including sepsis) is €3.7bn annually and sepsis specific POC diagnostics testing market is expected to grow from €1bn by 2026. To exploit this lucrative market opportunity, we must complete an innovation project to progress our highly promising results into a product suitable for a large-scale clinical validation, mass manufacturing and subsequently commercialization.